Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T67908
|
|||||
Target Name |
Globohexaosylceramide (Globo H)
|
|||||
Gene Name |
NOUNIPROTAC
|
|||||
Target Type |
Clinical trial target
|
[1] | ||||
Disease | [+] 1 Target-related Diseases | + | ||||
1 | Solid tumour/cancer [ICD-11: 2A00-2F9Z] | |||||
UniProt ID |
Drugs and Modes of Action | Top | |||||
---|---|---|---|---|---|---|
Clinical Trial Drug(s) | [+] 2 Clinical Trial Drugs | + | ||||
1 | OBI-888 | Drug Info | Phase 1/2 | Solid tumour/cancer | [2] | |
2 | OBI-999 | Drug Info | Phase 1/2 | Solid tumour/cancer | [3] |
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | Clinical pipeline report, company report or official report of OBI Pharma. | |||||
REF 2 | ClinicalTrials.gov (NCT03573544) This Study is to Evaluate Safe and Effective Treatment Dose of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors.. U.S. National Institutes of Health. | |||||
REF 3 | ClinicalTrials.gov (NCT04084366) Phase 1/2 Study of OBI-999 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health. | |||||
REF 4 | Preclinical Studies of OBI-999: A Novel Globo H-Targeting Antibody-Drug Conjugate. Mol Cancer Ther. 2021 Jun;20(6):1121-1132. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.